TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17656620
Drug: Vildagliptin 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 25, 50, 100, and 200 mg
Study: 17656620
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg with high-fat meal
Study: 11824859
Drug: AVP-V1-antagonist (d(CH2)5Tyr(me)AVP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP-V1-antagonist (d(CH2)5Tyr(me)AVP; 0.5 mg; AVPi)
Study: 8678512
Drug: 5-FU alone
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU alone or in combination with chemotherapeutic drugs
Study: 1855676
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy using a combination of 1:100,000 adrenaline and 5% ethanolamine
Study: 1855676
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy after rebleeding in conservatively treated group
Study: 6661730
Drug: Cholinergic drugs
Normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic drugs (physostigmine, pyridostigmine bromide, edrophonium chloride)
Study: 6661730
Drug: Anticholinergic drugs
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drugs (scopolamine, orphenadrine)
Study: 17684044
Drug: Hormone levels
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone levels measured at baseline and again at 3 and 6 months (total, free, and bioavailable testosterone, dihydrotestosterone, SHBG, LH, dehydroepiandrosterone, dehydroepiandrosterone sulfate, estrone, estradiol, cortisol)
Study: 15589567
Drug: bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion (150 mg, PO)
Study: 15589567
Drug: bupropion (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion (open-label treatment for 8 weeks)
Study: 23692553
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release topiramate (USL255)
Study: 21337293
Drug: Pharmaceutical consulting
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical consulting intervention by pharmacists regarding optimized antibiotic therapy
Study: 21337293
Drug: Pharmaceutical consulting
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical consulting intervention
Study: 17204956
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg 13C‐urea
Study: 17204956
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg 13C‐urea
Study: 9083731
Drug: Conventional sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sedation (pethidine 25-50 mg and midazolam 2.5 mg)
Study: 28825227
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for breast cancer
Study: 24717951
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 12 months
Study: 19389245
Drug: Focal Psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal Psychodynamic Therapy (FPT)
Study: 12170445
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m(2) plus carboplatin to an AUC of 6 every 3 weeks
Study: 12170445
Drug: vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25 mg/m(2) on days 1, 8, 15, and 22 plus cisplatin 100 mg/m(2) on day 1 every 4 weeks
Study: 9174680
Drug: Intravenous valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous valsartan (5, 10, and 20 mg)
Study: 9174680
Drug: Oral valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral valsartan (80 mg capsule)
Study: 9174680
Drug: Oral valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral valsartan (buffered solution, 80 mg)
Study: 9174680
Drug: Intravenous valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous valsartan (20 mg)
Study: 2859199
Drug: Bucindolol 150
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol 150 mg
Study: 23019938
Drug: Compound Xuanju
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xuanju Capsule (CXC) and Clomiphene Citrate (CC)
Study: 17901792
Drug: Nonfluoroquinolone antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfluoroquinolone antibiotics
Study: 16213381
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (five weekly intra-articular injections)
Study: 11825860
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg GHB/kg body wt
Study: 11825860
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg GHB/kg body wt
Study: 11825860
Drug: clomethiazole 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: clomethiazole 1000 mg daily (CLO group)
Study: 10553535
Drug: Gangliosides treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gangliosides treatment (100 mg/day for 15 days followed by 40 mg/day for 75 days)
Study: 10553535
Drug: Gangliosides treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gangliosides treatment (continuous treatment for 12 months)
Study: 10553535
Drug: Gangliosides treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gangliosides treatment
Study: 1869064
Drug: Acetyl-L-carnitine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (30 mg/kg)
Study: 6132179
Drug: melphalan 6
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan 6 mg/m2 daily for 5 days every 6 weeks for sixteen cycles
Study: 6132179
Drug: no additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: no additional treatment
Study: 30684327
Drug: 10 whole-body
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 whole-body cryotherapy treatments associated with 30-minute kinesitherapy
Study: 15802370
Drug: Phenylephrine (alpha(1)-agonist)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (alpha(1)-agonist)
Study: 12375540
Drug: Estrogen cream
Normalized name: ESTRIOL 4 mg in 85 g / ESTRADIOL 1 mg in 85 g TRANSDERMAL CREAM [BiEST 5.0 Estrogen Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen cream
Study: 9640069
Drug: Pelentan (Hypoprothrombinemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelentan (Hypoprothrombinemia Provocation Test) administered to patients with suspected hepatic injury and alcohol abusers
Study: 9640069
Drug: Pelentan (Hypoprothrombinemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelentan (Hypoprothrombinemia Provocation Test) administered
Study: 9640069
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (clinically healthy people not exposed to toxic agents)
Study: 31493725
Drug: tDCS applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tDCS applied during MT (concurrent‐tDCS group)
Study: 18387567
Drug: Finger-differentiation training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finger-differentiation training programme (G1) - 2 weekly sessions of half an hour each for 8 weeks
Study: 10027429
Drug: Zafirlukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (20 mg twice daily) with PEF variability >= 20%
Study: 10027429
Drug: Zafirlukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (20 mg twice daily) with PEF variability < 20%
Study: 2405348
Drug: aluminum ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: aluminum ibuprofen suspension for 2 weeks
Study: 2405348
Drug: control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (no treatment)
Study: 7008643
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg I.V.
Study: 22986242
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal therapy (nystatin, 1 or 3 times/week for 14 days)
Study: 20350598
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches with polyacrylate pressure sensitive adhesives
Study: 18671241
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg subcutaneously 3 times weekly)
Study: 18671241
Drug: Epoetin-alpha (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha (10,000 IU subcutaneously 3 times weekly)
Study: 15562376
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/d for 24 weeks)
Study: 7532192
Drug: L-selectin expression
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-selectin expression
Study: 1646613
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of apafant (20 mg to 400 mg)
Study: 1646613
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of apafant (100 mg t.i.d. over 7 days)
Study: 1646613
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of apafant (0.5 to 50 mg over 30 min)
Study: 1646613
Drug: Inhalative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalative administration of apafant (up to 1.0 mg)
Study: 1646613
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of apafant (capsules)
Study: 7148760
Drug: Both enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both enzyme preparations
Study: 29669748
Drug: 0 mg/mL
Normalized name: urea 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/mL e-liquid
Study: 29669748
Drug: 6 mg/mL
Normalized name: phenol 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/mL e-liquid
Study: 29669748
Drug: 12 mg/mL
Normalized name: niacin 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/mL e-liquid
Study: 29669748
Drug: 24 mg/mL
Normalized name: sulfur 24 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg/mL e-liquid
Study: 27922279
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix) at low dose
Study: 19234342
Drug: Sub-Tenon's injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's injection of 25 mg triamcinolone and 2 mg ciprofloxacin in biodegradable microspheres
Study: 17768459
Drug: Standard plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard plus relaxation therapy, 2 times per week, for 8 weeks
Study: 12439918
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy after gastrectomy
Study: 7577778
Drug: 0.05% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% bupivacaine at 10 mL/h
Study: 7577778
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine at 10 mL/h
Study: 7577778
Drug: 0.01% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% bupivacaine at 10 mL/h
Study: 7577778
Drug: 1 mg/h
Normalized name: fentanyl 0.1 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/h bupivacaine
Study: 83475
Drug: Inactivated influenza-A
Normalized name: influenza A virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza-A vaccine
Study: 83475
Drug: Annual revaccination
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual revaccination with inactivated influenza-A vaccine
Study: 23789838
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with Sebium H2O Micellaire Solution (Control)
Study: 21407074
Drug: tCSA once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tCSA once daily (n = 50)
Study: 21407074
Drug: tCSA twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tCSA twice daily (n = 50)
Study: 17369597
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) for chronic fatigue syndrome
Study: 11473555
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas inflow of 1.0 L min-1
Study: 11473555
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas inflow of 2.0 L min-1
Study: 9724561
Drug: Ranitidine 75
Normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 75 mg b.i.d. for 8 days
Study: 9724561
Drug: Racemic chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic chlorpheniramine 4 mg single oral dose
Study: 8056698
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg i.v. tds
Study: 8056698
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg po bd
Study: 2451231
Drug: Porous titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous titanium steroid eluting electrode with dexamethasone sodium phosphate
Study: 2451231
Drug: Porous titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous titanium electrode without steroid
Study: 12587122
Drug: Talinolol (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol (four marketed tablet formulations)
Study: 10678268
Drug: no-drug control
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-drug control state
Study: 3539163
Drug: Epoprostenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol infusion (5 ng/kg/min, mean dose 4.9 ng/kg/min, 72 hour infusion)
Study: 26242047
Drug: Shugan Jieyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Jieyu Capsules (SJC)
Study: 20936994
Drug: Inhaled montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled montelukast 100 μg
Study: 20936994
Drug: Inhaled montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled montelukast 250 μg
Study: 20936994
Drug: Inhaled montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled montelukast 1000 μg
Study: 20936994
Drug: Montelukast (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (pooled doses) plus albuterol
Study: 12930168
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.35 g.kg(‐1).d(‐1) for 7 days)
Study: 12412676
Drug: Terbutaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.5 mg
Study: 27354202
Drug: Amitriptyline (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (tricyclic antidepressant)
Study: 6438686
Drug: Clovoxamine (nontricyclic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clovoxamine (nontricyclic, experimental antidepressant)
Study: 31071760
Drug: 1% sodium
Normalized name: Dextrose 5% and 0.11% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sodium alendronate gel
Study: 25097010
Drug: Antiangiogenic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic drugs
Study: 19382637
Drug: Diaskintest (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaskintest (0.2 microg in 0.1 ml)
Study: 19382637
Drug: Tuberculin skin
Normalized name: tuberculin skin test; unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculin skin test (Mantoux test with 2 TE of PPD L-2)
Study: 17545533
Drug: Elacridar 100
Normalized name: Elacridar
DrugBank: Elacridar (DB04881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacridar 100 mg coadministered with oral topotecan 2.0 mg
Study: 17545533
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan 2.5 mg
Study: 17545533
Drug: Recommended schedule:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended schedule: 2.0 mg oral topotecan plus 100 mg elacridar
Study: 15837645
Drug: Irrigating solution
Normalized name: IRRIGATING SOLUTIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigating solution of Sihuang (ISSH)
Study: 16960944
Drug: Topical nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonsteroidal antiinflammatory drugs (NSAIDs)
Study: 10321415
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 or 300 mg/d)
Study: 10321415
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (100, 200, 300, or 400 mg/d)
Study: 10321415
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (50 to 150 or 100 to 300 mg/d)
Study: 8562960
Drug: G‐CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (300 micrograms subcutaneously)
Study: 1992393
Drug: Nifedipine (10‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10‐30 mg sublingually, then 40‐120 mg/day orally)
Study: 1992393
Drug: Hydralazine (6.25‐12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (6.25‐12.5 mg intravenously, then 80‐120 mg/day orally)
Study: 31444617
Drug: Fedratinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fedratinib (200 mg and above)
Study: 30024999
Drug: 0.2% chlorhexidine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine-based solution (positive control)
Study: 24750904
Drug: Ceftriaxone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone at a dose of 2 g, given every 24 hours intravenously for four days, in addition to stroke-unit care
Study: 21700408
Drug: RFA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFA treatment
Study: 17346705
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin applied at and just above the level of spinal cord injury
Study: 16259624
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (supervised sessions three times per week for eight weeks)
Study: 12177109
Drug: GSH (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSH (1,500 mg/m(2) over a 15-minute infusion before oxaliplatin)
Study: 7760093
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg methohexital
Study: 7760093
Drug: 2 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms/kg fentanyl and 0.15 mg/kg midazolam
Study: 7760093
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg ketamine and 0.15 mg/kg midazolam
Study: 23380426
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg twice daily for 9 days
Study: 23380426
Drug: Tolbutamide 500
Normalized name: tolbutamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide 500 mg single dose on Day 5
Study: 1672569
Drug: Luteinising-hormone releasing-hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinising-hormone releasing-hormone (LH-RH), 1.2 mg daily intranasally for four weeks
Study: 6555015
Drug: Cefonicid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1 g intramuscularly)
Study: 6555015
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg orally three times a day for 7 days)
Study: 30703077
Drug: Recombinant zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant zoster vaccine (RZV; Shingrix)
Study: 26563608
Drug: Ropivacaine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine continuous infusion (group R)
Study: 26563608
Drug: Saline continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline continuous infusion (placebo, group P)
Study: 24831421
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (gabapentin or pregabalin)
Study: 21898137
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 20 mg/kg IV over 15 min
Study: 21898137
Drug: Lorazepam (LOR)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (LOR) 0.1 mg/kg IV over 2-4 min
Study: 19713172
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d seaweed (Undaria pinnatifida)
Study: 19713172
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d seaweed
Study: 19713172
Drug: 6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/d seaweed
Study: 18549664
Drug: Doripenem 500
Normalized name: doripenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem 500 mg every 8 h by a 1-h intravenous infusion
Study: 18549664
Drug: Piperacillin/tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4.5 g every 6 h by 30-min IV infusion
Study: 16148021
Drug: Dose-dense sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense sequential chemotherapy with epirubicin (110 mg/m2) followed by paclitaxel (250 mg/m2) and intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2, fluorouracil 840 mg/m2)
Study: 16148021
Drug: Dose-dense sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense sequential chemotherapy with epirubicin followed by paclitaxel and intensified CMF
Study: 8850378
Drug: L-propionylcarnitine 500
Normalized name: arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-propionylcarnitine 500 mg tid for 6 weeks